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Abstract
Background: Methamphetamine (MA) use during pregnancy is associated with many pregnancy complications,
including preterm birth, small for gestational age, preeclampsia, and abruption. Hawaii has lead the nation in MA
use for many years, yet prior to 2007, did not have a comprehensive plan to care for pregnant substance-using
women. In 2006, the Hawaii State Legislature funded a pilot perinatal addiction clinic. The Perinatal Addiction
Treatment Clinic of Hawaii was built on a harm-reduction model, encompassing perinatal care, transportation,
child-care, social services, family planning, motivational incentives, and addiction medicine. We present the
implementation model and results from our first one hundred three infants (103) seen over 3 years of operation of
the program.
Methods: Referrals came from community health centers, hospitals, addiction treatment facilities, private physician
offices, homeless outreach services and self-referral through word-of-mouth and bus ads. Data to describe sample
characteristics and outcome was obtained prospectively and retrospectively from chart abstraction and delivery
data. Drug use data was obtained from the women’s self-report and random urine toxicology during the
pregnancy, as well as urine toxicology at the time of birth on mothers, and urine and meconium toxicology on the
infants. Post-partum depression was measured in mothers with the Edinburgh Post-Partum depression scale. Data
from Path clinic patients were compared with a representative cohort of women delivering at Kapiolani Medical
Center for Women and Children during the same time frame, who were enrolled in another study of pregnancy
outcomes. Ethical approval for this study was obtained through the University of Hawaii Committee for Human
Studies.
Results: Between April 2007 and August 2010, 213 women with a past or present history of addiction were seen,
132 were pregnant and 97 delivered during that time. 103 live-born infants were delivered. There were 3 first-
trimester Spontaneous Abortions, two 28-week intrauterine fetal deaths, and two sets of twins and 4 repeat
pregnancies. Over 50% of the women had lost custody of previous children due to substance use. The majority of
women who delivered used methamphetamine (86%), either in the year before pregnancy or during pregnancy.
Other drugs include marijuana (59.8%), cocaine (33%), opiates (9.6%), and alcohol (15.2%). Of the women served,
85% smoked cigarettes upon enrollment. Of the 97 women delivered during this period, all but 4 (96%) had
negative urine toxicology at the time of delivery. Of the 103 infants, 13 (12.6%) were born preterm, equal to the
state and national average, despite having many risk factors for prematurity, including poverty, poor diet, smoking
and polysubstance use. Overwhelmingly, the women are parenting their children, > 90% retained custody at 8
weeks. Long-term follow-up showed that women who maintained custody chose long-acting contraceptive
methods; while those who lost custody had a very high (> 50%) repeat pregnancy rate at 9 months post delivery.
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any medium, provided the original work is properly cited.Conclusion: Methamphetamine use during pregnancy doesn’t exist is isolation. It is often combined with a
multitude of other adverse circumstances, including poverty, interpersonal violence, psychiatric comorbidity,
polysubstance use, nutritional deficiencies, inadequate health care and stressful life experiences. A comprehensive
harm reduction model of perinatal care, which aims to ameliorate some of these difficulties for substance-using
women without mandating abstinence, provides exceptional birth outcomes and can be implemented with limited
resources.
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Background
Methamphetamine (MA) use by pregnant women has
grown into the one of the greatest public health chal-
lenges of the 21
st century. Hawai’i arguably leads the
nation in the use of MA, especially among women,
given the highest percentages of female arrestees testing
positive for MA use are located in Honolulu (50%), San
Jose (42.8%), Phoenix (41.7%), Salt Lake City (37.7%),
and San Diego (36.8%) [1]. In addition, the use of MA
by women of childbearing age is increasing [2-4]. Indeed
MA has become the primary substance compelling drug
treatment during pregnancy [5]. Yet despite this epi-
demic, prior to 2007, Hawaii did not have a comprehen-
sive plan to care for pregnant substance-using women.
In this paper, we review what is known about MA use
in women and MA in pregnancy; the implementation
model for a perinatal clinic; and results from the first 97
women to deliver.
Women and Methamphetamine
Men’s rates of substance use disorders are nearly twice
as high as the rate for females (11.9 vs. 6.1 percent) [6].
However, women use MA at similar rates as do men.
The NSDUH 2009 data [6] showed that 0.2% of both
m e na n dw o m e nu s e dM Ai nt h ep a s ty e a r .I n2 0 0 7 ,
females accounted for 40% of stimulant-related ED visits
and 45% of MA-related treatment admissions in the
United States [7]. In comparison, men are three times
more likely to abuse alcohol and twice as likely to use
cocaine than women [6]. Reasons for this discrepancy
are multiple and need to be addressed during treatment.
Co-occurring Disorders
Women are more likely to have co-occurring mental
health disorders; as many as two thirds of women with
substance use disorders may have a co-occurring mental
health problem, including depression, post-traumatic
stress disorder, panic disorder and/or eating disorder
[8]. They are more likely to be victims of domestic vio-
lence, incest, rape, sexual assault, and child physical
abuse. This victimization has been linked to many nega-
tive outcomes, including posttraumatic stress disorder
(PTSD), depression, anxiety, suicidal behavior and low
self-esteem among women in the general population [9].
Women who are survivors of childhood sexual assault
are more likely to use alcohol and other drugs [10,11].
Posttraumatic stress disorder is strongly associated with
stimulant use disorders, including MA [12].
Methamphetamine, increasing the synaptic levels of
not only dopamine, but also norepinephrine and seroto-
nin, is a powerful antidepressant at first, which may par-
tially explain its allure to women. Semple et al [13]
showed that women who use MA had significantly
higher Beck Depression Index scores than men who
used MA. MA users in general have high levels of psy-
chiatric symptoms and psychological problems. One
study showed that women scored higher than men on
every psychological symptom at treatment entry, espe-
cially anxiety, depression, interpersonal sensitivity,
obsessive-compulsive disorder and somatization [14].
Weight Loss
In addition, many women begin using MA in order to
lose weight, as many as 36% of women in one study vs.
7% of men [15]. Piran and Robinson [16] showed high
rates of stimulant use among women with eating disor-
ders. Corstorphine et al [17] showed that women with
eating disorders who were victims of childhood sexual
assault were more likely to use alcohol, cocaine or
amphetamines. Gender roles stressing the thin-ideal
b o d yi m a g em a ye x a c e r b a t et h ep r o b l e m ,e s p e c i a l l y
among white, Native American and Pacific Island
women [18].
Caregiver role
Women who must hold down multiple jobs, including
caring for children often turn to MA to give them the
extra energy they need to be “supermom.” Though men
more often than women use methamphetamine to
“work more,” and are more likely to be employed than
women, women were more likely to use MA to stay
awake [15].
Cost
The cost of drugs may play a large role in initiation.
Women are more likely to live in poverty, and when
they do get drugs, it is usually from a partner who is
also using [15]. Methamphetamine acts longer than
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lation, cost less. One nickname for the drug is “poor-
man’s cocaine.” In addition, many studies have shown
t h a tw o m e nM Au s e r sa r em o r el i k e l yt ob eh o m e l e s s
[19].
Methamphetamines and Pregnancy
Despite the widespread nature of MA use in women of
childbearing age, little research has been done on its use
during pregnancy. Most prior drug use research was
conducted in response to the crack cocaine epidemic of
the early 1980s. Much remains unknown about the
effects of in utero MA exposure and fetal and infant
development. No consistent teratological effects of in
utero MA exposure on the developing human fetus have
been identified [20,21]. Given that women with sub-
stance use disorders suffer from chaotic lifestyles,
research on drug use during pregnancy is fraught with
difficulties. Studies of MA-exposed infants suffer from
methodological problems such as poor compliance,
small sample size and multiple other confounding vari-
ables, such as the effects of poverty, poor diet, and
tobacco use, which in studies of other drug use during
pregnancy have been found to be as harmful if not
more so than the drug use itself [22] Learning from past
mistakes from the crack cocaine epidemic, Barry Lester
and colleagues initiated the Infant Development, Envir-
onment, and Lifestyle (IDEAL) study in 2002 to study
the effects of prenatal methamphetamine exposure.
Investigators have enrolled 1,618 mothers at four clinical
centers in cities where methamphetamine use is proble-
matic, including Honolulu. Thus far the results from the
IDEAL study indicate that methamphetamine is asso-
ciated with fetal growth restriction [23], but no measur-
able difference in psychological functioning by age three
[24].
There is some limited data on the effects of MA use
on maternal complications during pregnancy [25-30].
With the exception of Cox et al [29], the numbers in
these studies are all small and suffering from the metho-
dological problems noted above. The Cox study showed
increased risks of hypertension complicating pregnancy,
premature rupture of membranes, placenta previa, pla-
cental abruption, premature delivery, precipitate labor,
infection of amniotic cavity, intrauterine death, and poor
fetal growth when compared with non-substance using
women, but when compared with cocaine-using women,
these risks were all less, with the exception of hyperten-
sion complicating pregnancy, which was increased over
cocaine.
Studies looking at birth weight and gestational age
show conflicting results, with most showing slightly
smaller babies and lower gestational ages [26,27,31,32].
Studies on neurodevelopment [33-37] have shown MRI
differences and small differences in performances on
some developmental measures, but with the exception
of the IDEAL study, longitudinal data is missing.
Harm Reduction and Pregnancy
With the exception of methadone maintenance, which is
currently the standard of care for opiate-dependent
pregnant women, harm reduction programs for preg-
nant substance-using mothers are rare, especially in the
United States. As stated by McGourty and Chasnoff:
“From a public health perspective, the concept of harm
reduction does not have a role in the care of pregnant
women [38].” Part of the problem is in the definition of
harm reduction. It refers to both a philosophical
approach and specific types of programs or interven-
tions [39]. Perhaps McGourty and Chasnoff miscon-
strued that harm reduction means simply tolerating
drug or alcohol use during pregnancy, which, especially
in the case of alcohol, goes against the necessary teach-
ing that no amount of alcohol is known to be safe dur-
ing pregnancy [40].
Prenatal care has been shown to ameliorate many of
the complications of drug use during pregnancy [41], so
it makes empiric sense that a harm reduction philoso-
phy as it facilitates entry into prenatal care, would
decrease pregnancy complications. There has been little
w r i t t e no nh a r mr e d u c t i o np r o g r a m sf o rp r e g n a n t
women, mostly originating from the U.K. and Canada,
though programs certainly exist in the U.S. The litera-
ture on harm reduction in pregnancy from the U.S.
mainly focuses on harm reduction by reducing use, not
specific programs. One specific program in Canada has
shown great promise with a harm reduction approach.
Poole stated in her evaluation of the Sheway project in
British Columbia [42]:
Particularly promising is harm reduction program-
ming offered to high-risk, marginalized pregnant
women and their support networks, an approach
that has been shown to prevent FAS and other alco-
hol- and drug-related disabilities, support retention
of custody, and increase the health and social stabi-
lity of both mothers and children
Key components of a harm reduction program should
focus on improving nutrition, decreasing smoking,
decreasing alcohol and drug use, encouraging breast-
feeding, promoting dental health and encouraging physi-
cal activity, encouraging early and continuing prenatal
care and promoting social and community support [43].
This review of the literature has shown many of the
important concepts that must be addressed when pro-
viding care to pregnant women with substance use dis-
orders. There are a few dozen programs that specifically
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little in the literature evaluating their effectiveness.
These concepts were used to build a comprehensive
program, which is described below.
Methods
Context
The clinic concept was developed starting in March
2005 when a group of community leaders started meet-
ing. Funding proposals were developed through a colla-
boration with the University of Hawaii, the Hawaii
Departments of Human Services and Health, ACOG
Hawaii Section and the Salvation Army Family Treat-
ment Center, led by one of the authors (TEW). When
federal grant proposals were not funded, the decision
was made to appeal to the Hawaii State Legislature for
funding. The Hawaii State Legislature passed legislation
establishing the clinic in 2006 with the initial sum of
$400,000. The clinic model was developed with input
from the University of Hawaii Ob/Gyn, Pediatrics and
Addiction Medicine, and based on the successful Mila-
gro clinic in Albuquerque, New Mexico. The clinic
opened in April 2007 in a 1500 square foot house on
the grounds of the Salvation Army Family Treatment
Center.
Clinic Mission
Our mission is to provide comprehensive perinatal clini-
cal and social services to women with a history of sub-
stance abuse, in a warm home-like setting free of
judgment, and supportive of each woman’s unique path
from pregnancy to capable parent.
Program Goals
1. Improve birth outcomes in women who use drugs
and/or alcohol during pregnancy.
2. Improve developmental and behavioral outcomes
for children whose mothers used alcohol or other drugs
during pregnancy.
3. Provide an educational environment for residents,
students, and nurses to learn about the care of this
high-risk population in a sensitive manner.
4. Provide educational resources to the community in
order to decrease the prevalence of drug use among
pregnant and postpartum women.
5. Provide an environment to promote research on
substance abuse treatment, its effects on the mother,
fetus, and child, and prevention.
Clinic Services
The initial clinic services began with prenatal and post-
partum care. Deliveries were done by residents and staff
of the University of Hawaii at Kapiolani Medical Center
for Women and Children and Queens Medical Center.
Childcare was provided on site, transportation was pro-
vided either by taxi or by bus passes. Addiction psychia-
try services were provided by addiction psychiatry and
addiction medicine resident fellows under the supervi-
sion of one of the authors (WFH). Social services were
provided on site, including case management, assistance
with housing, substance abuse assessments and referral
to more intensive treatment if indicated and desired.
Group classes were provided including childbirth, par-
enting, smoking cessation, healthy eating, and relapse
prevention. In addition, groups were established includ-
ing self-nurturing group and craft groups to build self-
esteem and enhance maternal infant bonding as well as
relationship groups to addre s st h en e e d so ft h ew o m e n
and their partners. Healthy food was provided to
women while attending classes and clinic appointments,
and by year three, we had obtained a grant from the
Office of Hawaiian Affairs to provide a healing garden
on site. With this garden, we were able to grow a good
proportion of the fruits and vegetables provided to the
women. While we were unable to engage the services of
a dedicated pediatrician to meet goal (2) in the first
three years of operation, collaboration and referrals were
made with staff pediatricians at Kapiolani Medical cen-
ter and sympathetic community pediatricians.
Medical Care
Prenatal visits were scheduled every 2 weeks, given the
high-risk nature of these pregnancies, and the ability to
engage women more frequently in social services if they
came for medical care. Ultrasounds were generally
scheduled every 4-8 weeks after 20 weeks to watch for
intrauterine growth restriction and promote maternal
bonding. As much as possible, all laboratory tests were
done on site. Each woman received testing and counsel-
ing for HIV and Hepatitis C. Addiction psychiatry and
group classes were scheduled around clinic visits.
Counseling approach
All clinic staff, including medical assistants and resi-
dents, was trained in Motivational Interviewing techni-
ques [44], using a Stages of Change Model [45]. In
addition, counseling was trauma informed [46,47], given
high rates of childhood sexual assault in the clinic popu-
lation. As much as possible, a patient-centered harm
reduction approach was used. Women were encouraged
to participate in as many or as few activities as they
were comfortable with.
Motivational Incentives
Contingency management, in which patients receive
incentives or rewards for meeting specific behavioral
goals (e.g., verified abstinence), has particularly strong,
consistent, and robust empirical support across a range
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approaches are based on principles of behavioral psy-
chology and operant conditioning, in which behavior
that is followed by positive consequences is more likely
to be repeated [48]. We received a grant from the local
March of Dimes office to provide motivational incen-
tives for women to help overcome barriers to clinic par-
ticipation. Recognizing that getting clients through the
door was the biggest barrier, the women received an
initial $50 gift card for their first visit. This was reduced
to $20 after the first year based on studies done by
Petry and others recommending nominal and intermit-
tent rewards [49]. After completion of the psychosocial
assessment, they were awarded with an additional $20
gift card. In addition, they received picks from the “fish-
bowl” for each subsequent doctor’s visit, to reward
group attendance and taking steps toward goal achieve-
ment. The fishbowl had small tokens saying “good job,”
“small,” or “large.” Small gifts were usually baby or toil-
etry items of nominal cost and the large gifts were $50
gift cards.
Ethical Approval
The University of Hawaii Committee on Human Studies
reviewed the project and found it to be exempt from
consent requirements in order to report clinical
outcomes.
Outcomes
Data to describe sample characteristics and outcome
was obtained prospectively and retrospectively from
chart abstraction and delivery data. Drug use data was
o b t a i n e df r o mt h ew o m e n ’s self-report and random
urine toxicology during the pregnancy, as well as urine
toxicology at the time of birth on mothers, and urine
and meconium toxicology on the infants. Post-partum
depression was measured in mothers with the Edin-
burgh Post-Partum depression scale, where a score of
10 or more is indicative of high levels of depressive
symptomatology. For comparison, data on birth out-
comes of Path clinic patients were compared with those
of a representative cohort of women delivering at Kapio-
lani Medical Center for Women and Children during
the same time frame, who had been recruited for the
Pacific Research Center on Early Human Development
study (PRCEHD). The data on this cohort has been pre-
sented in a previous paper [30].
Statistical Analysis
Data was analyzed using SAS 9.2 (Cary, NC). Conven-
tional descriptive statistics were used. Dichotomous data
were compared using chi-square and continuous data
compared using student T-test. In order to further eval-
uate program effectiveness, we developed an outcome
score in 4 separate domains: birth outcomes, drug use,
custody, and repeat pregnancy. For each domain, several
indicators were considered and scored with a binary
coding scheme where 1 indicated a poor outcome and 0
an outcome within the normal range (see table five foot-
notes for the list of indicators mapping each outcome
domain). The indicators scores were then summed up
into a total domain score that was subsequently dichoto-
mized into a 0/1 binary summary score. For each
domain score, we conducted a series of bivariate ana-
lyses of several candidate predictors, including engage-
ment in prenatal care, parity, maternal medical
condition, psychosocial variables (domestic violence,
custody loss,..), drug use variables, and residential treat-
ment status. Each candidate predictor was retained for
logistic regression modeling based on a p-value < 0.25
in bivariate analysis. Multiple logistic regression models
were subsequently performed with stepwise selection of
candidate predictors. Throughout, a p-value of 0.05 was
retained as the criterion for statistical significance. The
fit of multiple logistic regression models was assessed
with the Hosmer-Lemeshow statistic.
Between April 2007 and August 31, 2010, 213 women
were seen for medical care. These women all had a his-
tory of addiction and were either actively using or in
early abstinence and thus at risk for relapse. There were
132 pregnant mothers and 97 of those delivered 103
live-born infants during that time, including two sets of
twins and 4 repeat pregnancies. There were 3 first-tri-
mester spontaneous abortions and two 28-week interu-
terine deaths (IUFD) thought to be secondary to
cytomegalovirus (CMV) exposure. Patients were seen for
a mean of 7 prenatal visits (range 1-19). Demographics
are shown in table 1.
Table 1 Demographics and clinical characteristics of Path
women compared with a cohort of women delivering at
the same hospital over the same timeframe
Path Clinic Kapiolani p-value
Mean SD Mean SD
Age 28.3 6.5 28.6 6.6 0.65
Gravidity 4.5 3.1 2.9 2.1 < 0.001
Parity 2.3 2.2 1.2 1.4 < 0.001
Abortions 1.2 1.9 0.7 1.1 0.01
Gestational Age 38.5 2.4 38.5 2.0 0.83
Birth Weight 3159.2 622.4 3189.9 552.2 0.61
N = 97 Percent N = 872 Percent
Native Hawaiian 47 49.5% 193 22.1 < 0.001
Smoking at delivery 65 63% 87 10% < 0.001
Methamphetamines
during pregnancy 68 66 22 2.5 < 0.001
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T h e r ew a sav e r yh i g hr a t eo fa s t h m ai nt h eP a t hc l i n i c
group (28%) compared with the Kapiolani cohort (KC)
(3.7%) p < 0.001. Chronic hypertension rates were also
higher than in the KC sample (9.9% vs. 4.5% p = 0.02).
In the Path sample, there were no cases of HIV and
6.2% had Hepatitis C. There were two cases of maternal
heart disease, which were possibly related to MA use.
One woman had pregestational diabetes. Co-occurring
mental health disorders were present in 36% of the
women, including 27% with depression, 10% with diag-
nosed PTSD, and 5% with bipolar disorder.
Psychosocial Stressors
In the Path sample, there were high rates of reported
interpersonal violence, including 55% with a history of
child-abuse or neglect and 62.5% with a history of
domestic violence. Ninety five percent of the women
were on Medicaid.
Drug use
MA was overwhelmingly the drug of choice for these
women (86%), though twenty-four percent used more
than one drug. Almost all women stopped or decreased
the use of drugs, with equal amounts of women becom-
ing abstinent in each trimester and only 6.3% continuing
to use until delivery. Only 5% of the infants’ toxicology
screens were positive. Of the eight opiate-dependent
women (one woman only admitted to using occasional
“pills” including oxycodone), 5 were on methadone
maintenance, 1 was on buprenorphine, and 2 women
were detoxified before being admitted to residential
treatment and before coming to the clinic. Drug use
characteristics are shown in table 2.
Eighty four percent of the women smoked at the
beginning of pregnancy, and only 14 percent of women
were able to quit during pregnancy, though 34 percent
decreased usage.
Pregnancy complications and birth outcomes are
listed in table 3. There were higher rates of preeclamp-
sia in the Path sample compared with the KC sample,
but most other pregnancy complications, notably pre-
term delivery, low birth weight, and cesarean delivery
rates showed no difference. We have no comparison
data for infant outcomes in the KC data, but rates of
newborn intensive care admissions in the Path sample
are relatively low, and 88.1 percent of infants were dis-
charged with their mothers. There were no cases of
intraventricular hemorrhages, necrotizing enterocolitis
or neonatal death. Of 58 neonates for whom we have
full pediatric information, there was only one major
anomaly diagnosed shortly after birth and 5 minor
anomalies, including 3 hydroceles and 2 minor digit
defects.
Table 2 Substance Use Characteristics
Drug Use N = 97 %
Methamphetamines 87 86.1
1st trimester 19 19.8
2nd trimester 22 22.9
3
rd trimester 21 21.9
Continuous 6 6.3
Cocaine 30 33
Marijuana 55 59.8
Opiates 9 9.6
Smoker 79 84
Alcohol 14 15.2 11-1st trimester use
only
Baby toxicology + (mec or
urine)
4 5.1
Smoking
Non-Smoker 15 16
Quit during pregnancy 14 15
Decreased during pregnancy 34 36
Stayed same 30 32
Increased 1 1.1
Table 3 Pregnancy complications
Path
Clinic
Kapiolani p-
value
N Percent N Percent
IUGR 5 5.0% N/A
Preeclampsia 11 11.0 35 4.0 0.0025
Preterm labor 11 10.9 112 12.8 0.58
PPROM 6 5.9 28 3.2 0.16
Abruption 2 2.0 N/A
Diabetes 8 8.0 113 12.9 0.22
Oligohydramnios 3 3.0 23 2.6 0.84
Previa 1 1.0 N/A
Chorioamnionitis 6 5.9 N/A
Non-reassuring fetal
heart
N/A
tones 6 5.9
Polyhydramnios 6 5.9 N/A
Cesarean section 34 33.0 252 29.0 0.39
Delivery < 37 weeks 13 12.6 131 15.0 0.70
Delivery < 32 weeks 1* 0.9 14 1.6 0.80
LBW 14 13.6 85 9.7 0.22
VLBW 2* 1.9 10 1.1 0.49
NICU admission 15 16.1 N/A
Hypoglycemia 3 4.7 N/A
Hyperbilirubin 11 10.8 N/A
sepsis 1 1 N/A
RDS 5 4.9 N/A
* 1 set of twins. 1 very preterm birth, but 2 very low-birth weight infants.
EBL = estimated blood loss, LBW = low birth weight < 2500 g, VLBW = very
low birth weight < 1500 g, NICU = neonatal intensive care unit, RDS =
respiratory distress syndrome, IVH = interventricular hemorrhage
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Data on post-partum follow-up, including incidence of
post-partum depression, contraceptive methods, and
repeat pregnancy rates are shown in table 4.
Twenty-one percent of women screened positive for
possible postpartum depression with an Edinburgh post-
partum depression scale of over 10. Twenty eight per-
cent of women chose long-acting reversible
contraception and 14% chose sterilization. Overall, 63%
of women chose some form of contraception immedi-
ately post-partum.
Analysis of poor outcomes
Outcome analyses
Outcome analysis is presented in table 5. The table
summarizes 4 independent logistic regression models
for each of the 4 outcomes considered. For each
outcome, only predictors that were significant at p <
0.05 are presented in the Table, with their correspond-
ing odds-ratio adjusted for the effects of other
predictors.
Infant outcomes were influenced by maternal parity
(protective), maternal medical conditions, and domestic
violence, when controlled for amount of prenatal care
and homelessness. Drug use was most heavily influenced
by residential treatment (highly protective) and lack of
prenatal care. Loss of custody was also strongly asso-
ciated with the protective presence of residential treat-
ment (AOR = 0.035) and an eight-fold increase in risk
due to third trimester drug use. Family planning failure
was associated with custody loss.
Discussion
This paper shows the success and challenges in caring
for this high-risk population. Women in this study had
high rates of co-occurring medical and mental health
problems, high poverty rates, high rates of interpersonal
violence, and high smoking rates. Despite these chal-
lenges, with the appropriate interventions and care,
women with addictions can have relatively normal birth
outcomes. Previous work by one of the authors showed
a 4-fold increased risk of preterm delivery with metham-
phetamine use in this population [30]. We definitely did
not see this increase, as our preterm delivery rate was
not different from the cohort from the same hospital, as
well as state and national averages (12.8 and 12.3
respectively) [50]. We did see increased preeclampsia
rates, which are not surprising as asthma, chronic
hypertension, and methamphetamine use are all asso-
ciated with preeclampsia [29].
By providing a safe environment to obtain prenatal
care, we ameliorated many the effects of the drug use,
especially preterm delivery rates. We have shown that
increased prenatal visits, which roughly translates into
participation with other clinic services is associated with
increased abstinence and decreased relapse postpartum,
though this could be a result of selection bias. Other
authors have shown this with other drugs [51]. Quality
prenatal care of at least 4 visits has been shown to sig-
nificantly improve birth outcomes, decrease preterm
delivery, and increase fetal birth weights [41]. Studies
with cocaine-using pregnant women demonstrate that
“comprehensive care” increases the likelihood of carry-
ing to term, having fewer complications, being drug free
at delivery, and having fewer exposed repeat pregnancies
[52].
Our experience has shown us the importance of a
comprehensive approach to treating women with addic-
tion. It is important to address all components of the
woman’s life, including work and family: As one of our
clients said, “I began using because I was working
Table 4 Postpartum follow-up
n %
Postpartum Depression 22 21.4
LARC 28 28
Sterilization 14 14
OCPS/Ring 12 12
DMPA 7 7
None 15 15
Lost 22 22
Female Partner only 2 2
Repeat pregnancy 13 17
DMPA=depo medroxyprogesterone acetate, LARC=long-acting reversible
contraception. OCPS=oral contraceptive pills.
Table 5 Predictors of poor outcomes in 4 domains
Infant Poor Outcomes* AOR 95% confidence interval
Parity 0.6 (0.4-0.9)
History of Domestic
Violence 5.7 (1.3-26.6)
Maternal Medical
Condition 4.6 (1.1-18.9)
Drug Use Poor Outcomes**
Residential Treatement 0.17 (0.031-0.95)
Poor prenatal care 12.7 (2.8-57.1)
Custody Loss Poor Outcomes***
Residential Treatement 0.035 (0.004-0.3)
3rd trimester drug use 7.9 (2.2-27.6)
Family Planning Poor Outcome****
Custody loss 2.7 (1.02-6.9)
Note: each domain summarizes outcome as measured by the following
indicator variables:
*preterm delivery, LBW, NICU admission, baby Length of stay > 4 days
**positive toxicology at birth (mom or baby), relapse within 6 months
***not discharged with baby (secondary to child welfare) or lost custody
within 6 months.
****not on birth control postpartum or repeat pregnancy within 6 months
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Page 7 of 10nights. My parents don’t speak English and have many
health problems, so I would have to get up after just
and hour or two of sleep and take them to their doctors’
appointments. I used ice [MA] to have energy to do
that.” Addressing nutrition is very important for exam-
ple, as weight gain can be a powerful trigger for relapse,
especially postpartum. One woman in our clinic stated
that she was very unhappy with her weight postpartum
which hadn’t been a problem with her past pregnancies
as she “just started using again and the weight came
right off.”
We believe a harm-reduction approach does work
with these women, as we had high rates of engagement
in services. As the clinic is in a house, many women sta-
ted they felt extremely comfortable there and would
come when in crisis or just “to hang out.” We had very
high rates of abstinence during pregnancy, despite not
mandating an abstinence-only approach. We believe this
approach encourage honesty about their use. The
women felt very comfortable discussing their use, and
many times would disclose their relapses before a posi-
tive toxicology result was obtained.
Another success is the relatively low rates of post-par-
tum depression, being fairly comparable to population-
based rates of 14-21% [53,54], given the high incidence
of antecedent depression in this population, and that a
history of depression is one of the biggest risk factor in
postpartum depression [53]. Having a safe, supportive
environment postpartum was cited by many women as
helpful to their general wellbeing.
The low rates of HIV and Hepatitis C point to the suc-
cess of other harm reduction approaches; Hawaii was the
first state in the nation to have a syringe-exchange pro-
gram, which has been operating since 1990 and the major-
ity of women in Hawaii smoke MA rather than inject.
The high rates of asthma are concerning, exceeding
Hawaii’s traditionally elevated rates of approximately
11% of the female population [55], and there are multi-
ple explanations: higher asthma rates among Native
Hawaiians; extremely high smoking rates in this popula-
tion, and possibly the concomitant use of albuterol with
MA to potentiate its effects. The high percentage of
Native Hawaiians in this clinic population points to a
large health disparity, which we have described before
[30], and needs to be addressed with community-based
research models.
The protective effect of residential treatment is seen
within the drug use and custody domains. This result is
to be expected as the residential treatment facility is the
only one on the island of Oahu that allows women to
bring a child into treatment with them. Women often
chose this center in order to maintain custody. This
type of program has demonstrated success in other
areas and should be expanded.
The effect of a history of domestic violence on poor
infant outcome is somewhat surprising, but not entirely
unexpected, given high levels of psychosocial stress is
associated with higher cortisol levels, and worse preg-
nancy outcomes [56]. Not surprising is the effect of
maternal medical conditions on infant outcomes.
Women should ideally enter pregnancy in optimal
health, medically as well as mentally to insure the health
of the infant.
While the majority of women were able to stop using
drugs during pregnancy, they continued to smoke cigar-
ettes. This is concerning given emerging data by us and
others that smoking may be more harmful than MA use
(at least on measurable pregnancy outcomes) [23]
( W r i g h te ta l :The placental and pregnancy effects of
methamphetamines and smoking, submitted) Chang, L.
et al (personal communication, Hawaii Addictions Con-
ference, March 19, 2010). While the numbers are too
small to show any association with MA and congenital
anomalies, it is reassuring that there were no large
increases in these rates over baseline.
These women have high gravidity and parity, and a
majority of these women have previously lost custody of
at least one child. Most of the women in the “none”
category were clients of a six-month residential treat-
ment facility which permitted no sexual contact and
thus thought themselves not to be at risk for pregnancy.
Of the 78 women we have information on, only 17%
became pregnant again within 18 months. Statewide,
21% of Medicaid women became pregnant within 15
months [57]. We showed that women who lost custody
were 2.5 times more likely to not use reliable contracep-
tion and have repeat pregnancies. Helping women main-
tain custody seems to encourage women to chose
reliable contraception. Our low repeat pregnancy rates
is a great success.
There is room for improvement in the postpartum
period, however, as 22% of the women were lost to fol-
low-up. Of the women who did follow up, there was a
1 3 %r e l a p s er a t et oh e a v yu s a g ea t6m o n t h s .A d d i t i o n
of pediatric care will help to keep women involved with
the clinic, and allow long-term follow-up of the children
and their outcomes.
Conclusion
Methamphetamine use during pregnancy doesn’t exist is
isolation. It is often combined with a multitude of other
adverse circumstances, including poverty, interpersonal
violence, psychiatric comorbidity, polysubstance use,
nutritional deficiencies, inadequate health care and
stressful life experiences. A harm-reduction approach,
which aims to ameliorate some of these difficulties for
substance-using women without mandating abstinence,
can work to engage women into prenatal care and
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Page 8 of 10normalize birth outcomes. This model provides an inex-
pensive and cost-effective approach (as the cost of one
preterm infant can exceed the $200,000 annual cost of
the program [56]) to affect community-wide change.
Having a clinic available in the community seemed to
improve screening rates for substance use disorders in
the community physicians, as there was a resource avail-
able for referral of these often-marginalized women and
their families. Directions for further study would be to
compare a harm reduction approach to traditional treat-
ment paradigm, e.g. adding cognitive behavioral therapy
(CBT). Also a comparison study of MA-exposed preg-
nancies to non-MA exposed pregnancies will be possible
with the addition of additional women in the non-MA
group. Certainly the pediatric follow-up will add long-
term longitudinal data on the effects of MA on the chil-
dren and help guide interventions to ameliorate the
damage.
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